<DOC>
<DOCNO>1050119_business_story_4270156.utf8</DOCNO>
<TEXT>


The Telegraph - Calcutta : Business

 German firm on Ranbaxy buy list

 New Delhi, Jan. 18 (PTI): Ranbaxy Laboratories Ltd today said it would buy a German drug firm and acquire a brand in the US besides earmarking $100 million for investment in manufacturing in the next financial year.

 ?We are going to buy a German company and acquire a brand in the US... Typically we have been investing $100 million in manufacturing,? Ranbaxy CEO and managing director Brian W. Tempest said.

 The price pressure in the US market was increasing and the company has 50 products in the pipeline for FDA approval, he said.

 The US business contributes close to 50 per cent of Ranbaxy?s topline while Europe about 20 per cent.

 The Indian market accounts for 18-20 per cent of the homespun pharma major?s business.

 Dip in net profit

 Ranbaxy Laboratories today reported a 2.1 per cent year-on-year decline in net profit at Rs 743 crore for the financial year ended December 31, 2004.

 The consolidated sales of the company, however, grew 18 per cent to touch Rs 5333.3 crore, Ranbaxy said in a release.

 In the fourth quarter, Ranbaxy?s net profit was down 10.9 per cent at Rs 156.5 crore on a turnover of Rs 1423.5 crore.

 The company?s sales in the quarter grew 24 per cent on a year-on-year basis. 




</TEXT>
</DOC>